BioRestorative Therapies Q1 2025 Update
Ticker: BRTX · Form: 8-K · Filed: May 14, 2025 · CIK: 1505497
Sentiment: neutral
Topics: financial-results, business-update
TL;DR
BRTX dropped Q1 earnings, focus on business updates.
AI Summary
BioRestorative Therapies, Inc. announced its first quarter 2025 financial results and provided a business update on May 14, 2025. The company, formerly known as Stem Cell Assurance, Inc., is based in Melville, NY, and operates in the health services sector.
Why It Matters
This filing provides investors with the latest financial performance and strategic developments for BioRestorative Therapies, Inc. as of the first quarter of 2025.
Risk Assessment
Risk Level: medium — The filing is a routine update, but the company's financial performance and future prospects carry inherent risks typical of the biotechnology sector.
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — Registrant
- Stem Cell Assurance, Inc. (company) — Former Name
- May 14, 2025 (date) — Date of Report
- Melville, New York (location) — Principal Executive Offices
- 001-37603 (other) — SEC File Number
FAQ
What is the primary purpose of this Form 8-K filing?
This Form 8-K filing is to report the results of operations and financial condition, provide Regulation FD disclosures, and include financial statements and exhibits for BioRestorative Therapies, Inc. as of May 14, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on May 14, 2025.
What is the principal executive office address for BioRestorative Therapies, Inc.?
The principal executive offices are located at 40 Marcus Drive, Melville, New York 11747.
What was BioRestorative Therapies, Inc. formerly known as?
BioRestorative Therapies, Inc. was formerly known as Stem Cell Assurance, Inc.
What is the company's fiscal year end?
The company's fiscal year end is December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 14, 2025 regarding BioRestorative Therapies, Inc. (BRTX).